Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
302962-49-8
Molecular formula
C22H26ClN7O2S
Molecular weight
488.01 g/mol
Drug class
Multikinase inhibitorBCR::ABL1 and SRC-family tyrosine kinase inhibitor
Mechanism of action
Inhibits BCR::ABL1 and SRC-family kinases and additional kinases including c-KIT, EPHA2 and PDGFRβ. Inhibition of BCR::ABL1 kinase activity suppresses proliferation and survival of Philadelphia chromosome-positive leukaemic cells.
Indications / reported uses
Treatment of adults with newly diagnosed chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML)
Treatment of adults with chronic, accelerated or blast-phase CML resistant or intolerant to prior therapy, and selected Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) settings
Paediatric Ph+ CML in chronic phase in eligible patients; indications and treatment lines vary by label
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Dasatinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dasatinib Permitted Daily Exposure (PDE) report (the Dasatinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dasatinib Occupational Exposure Limit (OEL) report (the Dasatinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.